Natural Capsules Limited · NSE:NATCAPSUQ
Natural Capsules — Q1 FY2023 Earnings Presentation
34 slides from Natural Capsules's earnings presentation, Aug 12, 2022
Slide 1: Cover letter: Investor Presentation to BSE
NATURAL -, A "Ae —™® A Eee & oS co =; Iso ISO eee é Re eso C ) p S U L G S Cer Les Ey BE ey Le) Prseneeresti heko Quality Le 1 ow \ aa ME Haein ie ee * ‘nwgcen saves We wine LIMITED VG - Caps CORP & REGD OFFICE : “ TRIDENT TOWERS” No. 23, 4th Floor, 100 fect Road, Jayanagar 2nd Block, Bangalore-5600
Slide 2: Investor Presentation August 2022
naturalcapsules.com investor Presentation AUGUST, 2022
Slide 3: Safe Harbor
Safe Harbor PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the INVESTOR strategies, objectives and anticipated results
Slide 4: Inside this document
Inside this document PRESENTATION INVESTOR OVERVIEW CANVAS a) Lu i FINANCIAL INVESTMENT QUARTERLY = PERFORMANCE MERITS HIGHLIGHTS a rv) Lu oi —_) rv) oa 3 o) oi ¢ oc —_) Ee 3 Zz
Slide 5: Company Overview
naturalcapsules.com Company Overview
Slide 6: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was Incorporated as a Public Limite
Slide 7: Our Journey
Our Journey PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION INVESTOR ° NCL was ED ¢ Soon after, in ED ¢ 2003 was an ED ° The coming ED ° In 2005-2007, NCL ED ° In 2009-2012, ELD ° In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acquired 5 lines NCL acquired up
Slide 8: Our Journey: 2015 onward
2015 —- 2018: THE HURDLES WE GOING FORWARD FACED ON THE WAY By Q1IFY23, new generation machines were commissioned, Fall in oil and commodity prices led to economic 2019 onward NCL witnessed an increase in slowdown in African countries and caused a demand in both domestic and export markets, which re
Slide 9: Product Offerings
Product Offerings PRESENTATION Natural Capsules Limited manufactures a vast array INVESTOR capsules, including vegetarian capsules which they have ra Ba pioneered in India. Orr ii, ; es, The company in now foraying into API manufacturing with complex CAPSULES NaS high-end patented technology develop
Slide 10: Global Presence
Global Presence PRESENTATION Natural Capsules exports to 22 countries across 5 continents, bringing in sizable revenue from its export. INVESTOR % OF TOTAL SALES AFRICA CIS Ghana * Georgia 2.48» NTAEE) ¢ Uzbekistan Nigeria South Africa MIDDLE EAST Sudan Teele Swaziland Iraq Uganda CUM Velil aaa Zimb
Slide 11: Serving Leading Brands
Serving Leading Brands PRESENTATION With over 3 decades of experience in the pharma sector, NCL has garnered CUSTOMERS FOR MORE THAN excellent relationship with customers across 37 countries. The company is now 10 YEARS focused on acquiring customers who deal with regulated markets. INVESTOR ie Roto
Slide 12: Leadership Team
Leadership Team PRESENTATION INVESTOR Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR a lw E = a Wn lw — a) Wn a < " 1) — < Mr. Pramod Kasat Mr. C P Rangachar Mr. S G Belapure Mrs. Jyothi Mun
Slide 13: Business Canvas
naturalcapsules.com Business Canvas
Slide 14: Capsules Segment
Capsules Segment : Zz ¢ = With almost three decades of experience in the industry, Natural Capsules ie Limited is a leading manufacturer of hard capsules in India, its products 2nd a are exported to regulated and unregulated markets across the globe, . largest 5 following stringent applicable rules
Slide 15: Enhancing Capacities
Enhancing Capacities PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. INVESTOR CAPSULES MANUFACTURING CAPACITY The ability to deliver faster = 38 Crores planned cap
Slide 16: API Segment
API Segment : Zz ¢ = Natural Capsules Limited is now foraying into the API business segment i through its wholly owned subsidiary - Natural Biogenex Private Limited Greenfield Capex at rs (NBPL) incorporated in 2020. The APIs that will be manufactured are, rumkur spread across ps Prednisolone, Betam
Slide 17: API Segment (contd.)
API Segment conta, PRESENTATION ~ THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME INR 115 Crores - planned capital expenditure for setting up the DEXAMETHASONE INVESTOR facility 10 MT 19 MT ¢ NCL will be the only manufacturer of this product Planned Capacity Imports to
Slide 18: Production Linked Incentive (PLI) Scheme
The scheme intends to boost domestic manufacturing x of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-reliance and reduce import A committee on drug security constit
Slide 19: Focus on R&D
Focus on R&D PRESENTATION NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company's recent entry into the API business is 2 DSIR a testament to its firm belief in R&D. Recognised state of the INVESTOR art R&D facilities R&D SPENDS & KEY AREAS O
Slide 20: Sustainability
Slide 21: Sustainability
Sustainability PRESENTATION Initiatives Zero discharge facilities Solar power generation INVESTOR SUSTAINABLE SY) Solar concentrated heat generation funded by IREDA and (st company to receive UNIDO grant for patented solar concentrated heat generation dishes in India _—_ NCL believes in Recycling of
Slide 22: gure) ae
naturalcapsules.com Pa 3 ‘ a Ht gure) ae er
Slide 23: Profit & Loss Statement Summary
Profit & Loss Statement Summary PRESENTATION PARTICULARS (& IN CRORES) FY18 FY19 FY20 FY21 FY22 INVESTOR Revenue from Operations 54.76 59.78 61.55 79.51 135.07 Other Income 0.81 1.13 0.95 0.73 1.01 Total Income 55.57 60.91 62.50 80.24 136.10 Total Operating Expenses 49.35 54.89 56.25 68.58 109.69 EB
Slide 24: Balance Sheet Summary
Balance Sheet Summary PRESENTATION PARTICULARS (IN CRORES) FY18 FY19 FY20 FY21 FY22 INVESTOR Total Equity (Networth) 54.32 55.49 55.62 62.10 82.98 Non Current Liabilities 2.17 1.23 1.08 1.55 34.85 Current Liabilities 14.56 17.61 17.98 33.30 46.45 Total Equity and Liability 71.05 74.33 74.68 97.05 16
Slide 25: Cash Flow Statement Summary
Cash Flow Statement Summary : <x PARTICULARS ¢ IN CRORES) FY18 FY19 FY20 FY21 Py ; [e) Cash Flow from Operating Activities 5.34 2.09 6.90 5.78 1.16 z Cash Flow from Investing Activities (0.93) (7.06) (5.74) (8.54) (45.88) Cash Flow from Financing Activities (3.92) 4.28 (1.18) 2.52 46.02 Net increase
Slide 26: Investment Merits
naturalcapsules.com investment Merits
Slide 27: Growth Drivers
Growth Drivers PRESENTATION Uy a id uf INVESTOR Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit State-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal APIs in
Slide 28: Strategic Priorities
Strategic Priorities PRESENTATION NCL is geared to bring about & oP monumental changes in its approach towards its business. INVESTOR With the ongoing CAPEX, the STRATEGIC PRIORITY > ACTIONS TAKEN Company is enabling itself to ° Positioning the business to reduce margin * Collaborating with buyers w
Slide 29: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 30: Quarterly Updates
Quarterly Updates REVENUES EBITDA @ 6.36% @ 12.37% @ 71.910% @ 114.82% EBITDA MARGINS PAT ®110BPS © 2.65% @ 414 BPS @ 144.15% KEY EPS @® Q-0-QGrowth oO 6.81% ) Y-o-Y Growth @® 117.02%
Slide 31: Management Commentary
Management Commentary PRESENTATION “lam pleased to provide you with an update on our performance during the quarter. We have had a strong start to FY23, continuing our growth momentum from last year. The increase in topline was driven by a INVESTOR combination of higher realisation and higher volume
Slide 32: CAPEX Tracker
CAPEX Tracker PRESENTATION Natural Capsules is geared to make significant capital expenditures in the quarters to come and Is on track with its capsule business. The Company will focus on ramping up its endeavours in its API business in the coming quarters. INVESTOR Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY2
Slide 33: Profit & Loss Statement Summary (consolidated)
Profit & Loss Statement Summary (consolidated) PRESENTATION PARTICULARS @ IN CRORES) Q1FY22 Q4FY22 Q1FY23 INVESTOR Revenue from Operations 25.71 A1.55 44.19 Other Income 0.04 0.81 0.23 Total Income 25.75 42.36 44.42 Total Operating Expenses 21.46 33.41 35.06 EBITDA (excl. Other Income) 4.25 8.13 9.1
Slide 34: Thank You
il ( ) NATURAL naturalcapsules.com CAPSULES 315 Limited Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman Teme ars ai Cele) TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jaynaga